



# Now available for Medicare patients managing their diabetes with insulin\*<sup>1</sup>



FreeStyle Libre 3 app

## The world's smallest, thinnest<sup>‡</sup> sensor



Product images are for illustrative purposes only. Not actual patient data.

The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Medicare coverage is available for the FreeStyle Libre 3 system if the FreeStyle Libre 3 reader is used to review glucose data on some days every month. Medicare and other third party payor criteria apply. Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

\* Patients must meet Medicare eligibility coverage criteria. † Data based on total active Medicare patients with CGM readers. ‡ Among patient-applied sensors.

**References:** 1. Local Coverage Determination (LCD) L33822, Glucose Monitors, <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33822> 2. Data on file, Abbott Diabetes Care.

See page 2 for Important Safety Information.


# Introduce your patients to better glucose management<sup>\*†1-4</sup>

- **>1%** reduction of A1c in people with type 2 diabetes<sup>\*†4</sup>
- **41%** reduction in time spent in hypoglycemia among patients with type 2 diabetes<sup>\*§2,5</sup>
- **66%** reduction in diabetes-related hospital admissions<sup>\*6</sup>

**Easy for you. Easy for your patients<sup>\*†2</sup>.**

## MEDICARE COVERAGE ELIGIBILITY CRITERIA<sup>||7</sup>

The DME will work with you to ensure proper clinical necessity and documentation.

- 1 The beneficiary has diabetes mellitus; and,
  - 2 The beneficiary's treating practitioner has concluded that the beneficiary (or beneficiary's caregiver) has sufficient training using the CGM prescribed as evidenced by providing a prescription; and,
  - 3 The CGM is prescribed in accordance with its FDA indications for use; and,
  - 4 The beneficiary for whom a CGM is being prescribed, to improve glycemic control, meets at least one of the criteria below:
    - a. The beneficiary is insulin-treated; or,
    - b. The beneficiary has a history of problematic hypoglycemia
-  Scan QR Code, or follow the link below, for more information on Policy Specific Documentation Requirements for problematic hypoglycemia found in the Glucose Monitor, Policy Article (A52464): <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464>
- 5 Within six (6) months prior to ordering the CGM, the treating practitioner has an in-person or Medicare-approved telehealth visit with the beneficiary to evaluate their diabetes control and determines that criteria 1-4 above are met.

**Customer Care Team 1-844-330-5535** Available 7 days a week, 8AM to 8PM ET, excluding holidays

**Prescribe the FreeStyle Libre 3 system today**

FreeStyle Libre 3 

 **Abbott**  
*life. to the fullest.®*

\* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products. † Compared to self-monitoring blood glucose testing. ‡ In patients with type 2 diabetes treated with basal insulin or noninsulin therapy with mean baseline A1c levels of 10.1%. § REPLACE trial: a randomized, controlled trial to evaluate the impact of FreeStyle Libre glucose monitoring system (n=149) on HbA1c in people with type 2 diabetes (T2D) taking multiple daily doses of insulin at 6 months compared to blood glucose monitoring (BGM; n=75) || Patients must meet Medicare eligibility coverage criteria.

**References:** 1. Bolinder, J. *The Lancet* (2016): [https://doi.org/10.1016/S0140-6736\(16\)31535-5](https://doi.org/10.1016/S0140-6736(16)31535-5) 2. Haak, T. *Diabetes Ther* (2017): <https://doi.org/10.1007/s13300-016-0223-6> 3. Evans M, et al. *Diabetes Ther* (2022): <https://doi.org/10.1007/s13300-022-01253-9> 4. Wright, E. *Diabetes Spectr* (2021): <https://doi.org/10.2337/ds20-0069> 5. Data on file, Abbott Diabetes Care. 6. Fokkert, M. *BMJ Open Diabetes Res Care* (2019): <https://doi.org/10.1136/bmjdc-2019-000809> 7. Local Coverage Determination (LCD) L33822, Glucose Monitors, <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33822>

### Important Safety Information

Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.